argenx

argenx SE is a global biotechnology company based in Amsterdam, the Netherlands, founded in 2008. The company specializes in developing innovative immunology therapies aimed at treating severe autoimmune diseases. Its name reflects the spirit of teamwork and collaboration, which is central to its mission of creating impactful immunology solutions. The flagship product of argenx is Vyvgart (efgartigimod), the first approved FcRn blocker available in the U.S., Europe, and Japan. This therapy modulates the immune system to reduce pathogenic antibodies, addressing the needs of patients with severe autoimmune conditions. argenx also collaborates with partners to enhance drug delivery technologies, including exclusive access to Halozyme’s ENHANZE SC technology and a partnership with Elektrofi, Inc. to explore advanced delivery methods. The company places a strong emphasis on research and development, focusing on antibody engineering and immunology innovation. With a commitment to quality and patient safety, argenx aims to translate scientific breakthroughs into effective therapies for patients worldwide.